No Data
AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders
Insider Purchase: CEO & President of $AIM (AIM) Buys 60,110 Shares
Express News | AIM ImmunoTech Form4 Filing Shows CEO And President Thomas K Equels Bought 60,110 Shares At An Average Price Of $0.18/Share
AIM ImmunoTech Announces Data Pubished on Part 1 Study on Ampligen
AIM ImmunoTech Announces Publication Of Phase 1 Data From Roswell Park Study On Ampligen In Early-Stage Triple-Negative Breast Cancer In The Journal For ImmunoTherapy Of Cancer
AIM ImmunoTech Announces Publication of Breast Cancer Data From Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
No Data
No Data
